Briti idufirma on pälvinud pealkirju 80 miljoni dollari kogumiseks, et rahastada nende uurimistööd psilotsübiini depressioonil põhinev ravi. See on läbimurre maagilise seeneekstrakti kasutamisel terapeutilistel eesmärkidel.
The exploration of psilocybin and other psychedelics for medical treatments began in the late XNUMXs. Despite positive results, the research was stopped and became illegal in XNUMX, halting what could have revolutionised mental health treatments. However, in the past decade interest has been reignited. Despite the legal obstacles, a handful of studies have recently been conducted which show great potential.
Compass Pathways— Paving The Way?
Kompassirajad is the tech company that is paving the way, with research into a synthetic form of psilocybin. They aim to combat treatment-resistant depression. Additionally, it is thought that this treatment will aid those with OCD, sõltuvusprobleemid and anorexia, among other conditions.
Kompassirajad kirjeldavad raviplaani, mis kasutab nii meditsiinilisi kui ka terapeutilisi aspekte.
- Patsient kohtub ja vestleb spetsiaalselt koolitatud terapeudiga.
- In a comfortable environment the patient receives a dose of psilocybin. They wear an eye mask and listen to a music playlist especially for them. The therapist remains by their side for the XNUMX-XNUMX hour session.
- Patsiendid arutavad sessiooni terapeudiga, uurides käitumis- ja emotsionaalsete harjumuste positiivsete muutuste ideid.
Ajad on muutused
USA toidu- ja ravimiamet on juba pikka aega pöördunud (the very same organisation that banned psychedelic research in XNUMX), andis ettevõttele staatuse „Läbimurre”. Staatus antakse, kui
“… preliminary clinical evidence shows that it may demonstrate substantial improvement over available therapy”
Põhimõtteliselt on sellel potentsiaali saada paremat ravi kui see, mida praegu pakutakse!
Helge tulevik ...
Another positive sign is, of course, the $XNUMX million dollars the company has managed to raise. This includes funding from the likes of Paypal co-founder Peter Thiel. It is clear that psychedelic research has escaped from the underground, and is on the brink of becoming mainstream!
Compass Pathways hope to have the treatment on the market by XNUMX. Despite setbacks due to Covid-XNUMX, research continues into the treatment that could spell a bright future those living with depression.